Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2

Status

Recruiting 2Completed 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 6

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Sarcoma 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Colonic Neoplasms 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Immunoconjugates × Clear all
NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Ambrx, Inc.

Phase 2 Active not recruiting
72 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

MBrace Therapeutics

Phase 1/2 Recruiting
130 enrolled
Tumor-Agnostic

Neoplasms

NCT06797999 2026-01-28

ADCElerate1

Adcendo ApS

Phase 1/2 Recruiting
270 enrolled
Sarcoma

Sarcoma

NCT03255070 2024-02-01

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Ambrx, Inc.

Phase 1 Completed
106 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT01605318 2024-01-24

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Gilead Sciences

Phase 1/2 Terminated
92 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03489525 2022-03-28

MEDI2228

MedImmune LLC

Phase 1 Completed
107 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01915472 2021-08-19

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Gilead Sciences

Phase 2 Withdrawn
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡